| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphohistiocytosis, Hemophagocytic | 20 | 2023 | 266 | 6.360 |
Why?
|
| Hematology | 5 | 2022 | 241 | 2.030 |
Why?
|
| Neutrophils | 31 | 2023 | 3767 | 2.010 |
Why?
|
| Leukemia, Promyelocytic, Acute | 18 | 2024 | 251 | 1.750 |
Why?
|
| Macrophage Activation Syndrome | 3 | 2019 | 123 | 1.680 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 7 | 2012 | 286 | 1.570 |
Why?
|
| Neutropenia | 7 | 2023 | 885 | 1.490 |
Why?
|
| Histiocytosis | 2 | 2020 | 40 | 1.200 |
Why?
|
| Anemia | 8 | 2020 | 1508 | 1.080 |
Why?
|
| Hematologic Diseases | 5 | 2020 | 497 | 0.960 |
Why?
|
| Lactoferrin | 12 | 2006 | 100 | 0.920 |
Why?
|
| Myelopoiesis | 6 | 2009 | 134 | 0.910 |
Why?
|
| Leukocyte Disorders | 1 | 2023 | 13 | 0.910 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2019 | 240 | 0.870 |
Why?
|
| Gene Expression Regulation, Leukemic | 8 | 2019 | 645 | 0.860 |
Why?
|
| Tretinoin | 18 | 2022 | 522 | 0.830 |
Why?
|
| Bone Marrow | 8 | 2023 | 2911 | 0.800 |
Why?
|
| Thrombocytopenia | 7 | 2016 | 1174 | 0.790 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 9 | 2009 | 628 | 0.790 |
Why?
|
| Myeloid Cells | 7 | 2014 | 818 | 0.780 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 2020 | 177 | 0.760 |
Why?
|
| Periodicals as Topic | 4 | 2020 | 1469 | 0.760 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2020 | 532 | 0.720 |
Why?
|
| Pharmacy | 1 | 2021 | 92 | 0.660 |
Why?
|
| Ferritins | 3 | 2022 | 599 | 0.660 |
Why?
|
| Cell Differentiation | 26 | 2020 | 11461 | 0.650 |
Why?
|
| Mastocytosis, Systemic | 1 | 2020 | 102 | 0.630 |
Why?
|
| Nuclear Proteins | 10 | 2015 | 5793 | 0.590 |
Why?
|
| Granulocytes | 5 | 2009 | 551 | 0.590 |
Why?
|
| Receptors, Retinoic Acid | 4 | 2003 | 226 | 0.580 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2018 | 165 | 0.560 |
Why?
|
| Antibodies, Neoplasm | 2 | 2010 | 279 | 0.560 |
Why?
|
| Oxazines | 1 | 2019 | 340 | 0.550 |
Why?
|
| Blood Platelet Disorders | 1 | 2017 | 61 | 0.550 |
Why?
|
| Bone Marrow Diseases | 2 | 2017 | 233 | 0.540 |
Why?
|
| Neutrophil Activation | 3 | 2008 | 181 | 0.530 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2009 | 661 | 0.480 |
Why?
|
| Granulocyte Precursor Cells | 2 | 2005 | 49 | 0.480 |
Why?
|
| Publishing | 2 | 2020 | 837 | 0.470 |
Why?
|
| Blood | 2 | 2014 | 586 | 0.470 |
Why?
|
| Cytoplasmic Granules | 5 | 1998 | 575 | 0.440 |
Why?
|
| Collagenases | 8 | 1998 | 221 | 0.440 |
Why?
|
| Respiratory Burst | 3 | 2008 | 110 | 0.440 |
Why?
|
| Steroids | 1 | 2018 | 927 | 0.440 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 1116 | 0.440 |
Why?
|
| Haploinsufficiency | 2 | 2012 | 329 | 0.440 |
Why?
|
| Humans | 140 | 2024 | 759098 | 0.410 |
Why?
|
| Up-Regulation | 7 | 2012 | 4123 | 0.410 |
Why?
|
| Anemia, Sickle Cell | 2 | 2022 | 1055 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 4 | 2019 | 9131 | 0.400 |
Why?
|
| Coagulants | 1 | 2012 | 46 | 0.400 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2012 | 112 | 0.390 |
Why?
|
| Pyrazoles | 2 | 2019 | 1989 | 0.380 |
Why?
|
| Gene Expression Regulation | 16 | 2009 | 11903 | 0.380 |
Why?
|
| Factor VIIa | 1 | 2012 | 103 | 0.380 |
Why?
|
| Prednisone | 1 | 2016 | 1563 | 0.370 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2012 | 1396 | 0.370 |
Why?
|
| Immunosuppressive Agents | 4 | 2019 | 4099 | 0.360 |
Why?
|
| Anemia, Macrocytic | 4 | 2014 | 54 | 0.350 |
Why?
|
| Antibodies, Neutralizing | 1 | 2019 | 1930 | 0.340 |
Why?
|
| Heparin | 2 | 2016 | 1656 | 0.340 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 1849 | 0.340 |
Why?
|
| Editorial Policies | 2 | 2014 | 457 | 0.330 |
Why?
|
| Lymphopenia | 3 | 2019 | 280 | 0.330 |
Why?
|
| Transcobalamins | 6 | 1996 | 19 | 0.330 |
Why?
|
| Plateletpheresis | 2 | 2019 | 38 | 0.330 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2008 | 1173 | 0.330 |
Why?
|
| Promoter Regions, Genetic | 8 | 2011 | 5790 | 0.320 |
Why?
|
| Pyridines | 2 | 2019 | 2876 | 0.320 |
Why?
|
| Repressor Proteins | 6 | 2005 | 2982 | 0.320 |
Why?
|
| DNA-Binding Proteins | 11 | 2020 | 9587 | 0.320 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 1 | 1 | 2008 | 18 | 0.320 |
Why?
|
| Matrix Metalloproteinase 8 | 3 | 2005 | 56 | 0.310 |
Why?
|
| Hematopoietic Stem Cells | 11 | 2014 | 3384 | 0.310 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2008 | 30 | 0.310 |
Why?
|
| Dexamethasone | 1 | 2016 | 1927 | 0.310 |
Why?
|
| Inflammation | 8 | 2019 | 10746 | 0.310 |
Why?
|
| Ichthyosis | 1 | 2008 | 59 | 0.310 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 421 | 0.300 |
Why?
|
| Transcription Factors | 14 | 2009 | 12106 | 0.290 |
Why?
|
| Cytokines | 3 | 2019 | 7290 | 0.290 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2011 | 556 | 0.280 |
Why?
|
| Leukemia, T-Cell | 2 | 2004 | 101 | 0.280 |
Why?
|
| Neoplasm Proteins | 5 | 2014 | 3614 | 0.280 |
Why?
|
| Niacinamide | 1 | 2009 | 414 | 0.280 |
Why?
|
| Lymphocyte Count | 1 | 2009 | 776 | 0.280 |
Why?
|
| Homeodomain Proteins | 6 | 2009 | 2413 | 0.270 |
Why?
|
| Factor V | 3 | 2010 | 168 | 0.270 |
Why?
|
| DNA, Complementary | 4 | 1999 | 1991 | 0.270 |
Why?
|
| Myeloid Progenitor Cells | 2 | 2006 | 114 | 0.270 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2006 | 40 | 0.270 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 2 | 2005 | 130 | 0.260 |
Why?
|
| Anaplasma phagocytophilum | 4 | 2007 | 37 | 0.260 |
Why?
|
| Aging | 3 | 2013 | 8633 | 0.250 |
Why?
|
| Chemotaxis | 1 | 2008 | 598 | 0.250 |
Why?
|
| Multiple Myeloma | 2 | 2021 | 5136 | 0.250 |
Why?
|
| Phagocytosis | 2 | 2015 | 1535 | 0.240 |
Why?
|
| Immune System Diseases | 1 | 2007 | 258 | 0.240 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 1898 | 0.230 |
Why?
|
| Cell Degranulation | 1 | 2005 | 278 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2022 | 3606 | 0.230 |
Why?
|
| Anemia, Diamond-Blackfan | 3 | 2014 | 136 | 0.230 |
Why?
|
| Cell Line | 17 | 2014 | 15638 | 0.230 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 855 | 0.220 |
Why?
|
| Disease Management | 3 | 2020 | 2495 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 1 | 2006 | 306 | 0.220 |
Why?
|
| Leptin | 1 | 2011 | 1589 | 0.220 |
Why?
|
| Animals | 38 | 2020 | 167531 | 0.210 |
Why?
|
| Ambulatory Care | 1 | 2014 | 2775 | 0.210 |
Why?
|
| Hematopoiesis | 6 | 2019 | 2060 | 0.210 |
Why?
|
| Anticoagulants | 2 | 2021 | 4896 | 0.210 |
Why?
|
| Retinoids | 1 | 2003 | 99 | 0.210 |
Why?
|
| Hemophilia A | 2 | 2016 | 360 | 0.210 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 4526 | 0.200 |
Why?
|
| Leukocytosis | 1 | 2023 | 251 | 0.200 |
Why?
|
| Erythropoietin | 2 | 2010 | 719 | 0.200 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 13625 | 0.200 |
Why?
|
| Adult | 33 | 2024 | 219353 | 0.200 |
Why?
|
| Monocytes | 2 | 2009 | 2568 | 0.200 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2009 | 885 | 0.200 |
Why?
|
| Genetic Techniques | 1 | 2004 | 428 | 0.190 |
Why?
|
| Base Sequence | 12 | 2007 | 12442 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 10 | 2005 | 6132 | 0.190 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 1603 | 0.190 |
Why?
|
| Mice | 28 | 2020 | 80993 | 0.190 |
Why?
|
| Critical Care | 1 | 2014 | 2692 | 0.190 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2022 | 297 | 0.180 |
Why?
|
| HIV Infections | 5 | 2017 | 17126 | 0.180 |
Why?
|
| Prognosis | 9 | 2022 | 29559 | 0.180 |
Why?
|
| Blotting, Northern | 7 | 2003 | 1545 | 0.180 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2001 | 119 | 0.170 |
Why?
|
| Blood Donors | 2 | 2019 | 343 | 0.170 |
Why?
|
| Molecular Sequence Data | 13 | 2007 | 17611 | 0.170 |
Why?
|
| Sp1 Transcription Factor | 1 | 2000 | 140 | 0.170 |
Why?
|
| Aged | 30 | 2024 | 168615 | 0.170 |
Why?
|
| Mutation | 10 | 2022 | 29878 | 0.170 |
Why?
|
| Janus Kinase 1 | 1 | 2019 | 107 | 0.170 |
Why?
|
| Signal Transduction | 10 | 2019 | 23328 | 0.170 |
Why?
|
| Mycobacterium avium Complex | 1 | 1999 | 60 | 0.170 |
Why?
|
| Female | 46 | 2024 | 390174 | 0.160 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1999 | 76 | 0.160 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 300 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 11656 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2017 | 3414 | 0.160 |
Why?
|
| Gaucher Disease | 1 | 1999 | 110 | 0.160 |
Why?
|
| DNA | 8 | 1992 | 7235 | 0.150 |
Why?
|
| Catastrophic Illness | 1 | 2018 | 58 | 0.150 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2019 | 298 | 0.150 |
Why?
|
| Neonatal Screening | 1 | 2022 | 596 | 0.150 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 489 | 0.150 |
Why?
|
| Syndrome | 2 | 2015 | 3275 | 0.150 |
Why?
|
| Gelatinases | 2 | 1998 | 88 | 0.150 |
Why?
|
| Megakaryocytes | 2 | 2015 | 566 | 0.150 |
Why?
|
| Tandem Repeat Sequences | 2 | 2019 | 181 | 0.150 |
Why?
|
| Recurrence | 3 | 2023 | 8465 | 0.150 |
Why?
|
| Lymphocytosis | 2 | 1990 | 119 | 0.150 |
Why?
|
| Male | 36 | 2024 | 358602 | 0.150 |
Why?
|
| Transfection | 6 | 2005 | 5781 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 2062 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 8 | 2009 | 3772 | 0.140 |
Why?
|
| Middle Aged | 30 | 2024 | 219628 | 0.140 |
Why?
|
| Pyrimidines | 2 | 2019 | 2996 | 0.140 |
Why?
|
| Macrophage-1 Antigen | 3 | 2005 | 286 | 0.140 |
Why?
|
| Gene Expression | 4 | 2009 | 7583 | 0.140 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 95 | 0.140 |
Why?
|
| Factor V Deficiency | 1 | 1996 | 10 | 0.140 |
Why?
|
| Myeloproliferative Disorders | 1 | 2022 | 610 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 3617 | 0.140 |
Why?
|
| Trans-Activators | 4 | 2009 | 2857 | 0.130 |
Why?
|
| Antigens, CD34 | 4 | 2011 | 653 | 0.130 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 541 | 0.130 |
Why?
|
| Hemostatics | 2 | 2016 | 243 | 0.130 |
Why?
|
| Mice, Mutant Strains | 3 | 2020 | 1757 | 0.130 |
Why?
|
| Fibrinolytic Agents | 2 | 2016 | 2168 | 0.130 |
Why?
|
| Contusions | 1 | 2016 | 81 | 0.130 |
Why?
|
| Matrix Metalloproteinase 9 | 5 | 1998 | 633 | 0.130 |
Why?
|
| Morpholines | 1 | 2019 | 582 | 0.130 |
Why?
|
| HL-60 Cells | 3 | 2008 | 363 | 0.130 |
Why?
|
| Cells, Cultured | 10 | 2012 | 18937 | 0.130 |
Why?
|
| Anemia, Aplastic | 1 | 2017 | 228 | 0.130 |
Why?
|
| Intrinsic Factor | 2 | 1992 | 4 | 0.130 |
Why?
|
| Ribosomal Proteins | 3 | 2014 | 360 | 0.120 |
Why?
|
| Aminopyridines | 1 | 2019 | 564 | 0.120 |
Why?
|
| Hemophilia B | 1 | 2015 | 84 | 0.120 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2019 | 496 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 859 | 0.120 |
Why?
|
| Treatment Outcome | 13 | 2024 | 64867 | 0.120 |
Why?
|
| Laminin | 1 | 1996 | 405 | 0.120 |
Why?
|
| Combined Modality Therapy | 4 | 2016 | 8548 | 0.120 |
Why?
|
| Benzimidazoles | 2 | 2011 | 858 | 0.120 |
Why?
|
| Thromboembolism | 3 | 2010 | 1011 | 0.120 |
Why?
|
| Leucine | 2 | 2014 | 548 | 0.120 |
Why?
|
| Chromatin | 2 | 2003 | 2940 | 0.120 |
Why?
|
| Nitriles | 1 | 2019 | 954 | 0.120 |
Why?
|
| Membrane Glycoproteins | 4 | 2008 | 3684 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 7 | 2006 | 6070 | 0.120 |
Why?
|
| Prescription Fees | 1 | 2015 | 151 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 1000 | 0.120 |
Why?
|
| Folic Acid | 1 | 2001 | 1303 | 0.120 |
Why?
|
| Factor VIII | 1 | 2016 | 349 | 0.110 |
Why?
|
| RNA, Messenger | 11 | 2002 | 12765 | 0.110 |
Why?
|
| Tamoxifen | 2 | 2010 | 962 | 0.110 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1997 | 788 | 0.110 |
Why?
|
| Interferon-gamma | 2 | 2016 | 3123 | 0.110 |
Why?
|
| Hemoglobins | 3 | 2020 | 1517 | 0.110 |
Why?
|
| Benzoates | 1 | 2015 | 212 | 0.110 |
Why?
|
| Neoplasms | 5 | 2022 | 22023 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2019 | 2914 | 0.110 |
Why?
|
| Hydrazines | 1 | 2015 | 224 | 0.110 |
Why?
|
| Erythroid Precursor Cells | 2 | 2011 | 211 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 4111 | 0.110 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2015 | 551 | 0.110 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 12963 | 0.110 |
Why?
|
| Methotrexate | 1 | 2020 | 1715 | 0.110 |
Why?
|
| Bone Marrow Cells | 5 | 2014 | 2419 | 0.110 |
Why?
|
| Platelet Factor 4 | 1 | 2013 | 129 | 0.110 |
Why?
|
| Patient Advocacy | 1 | 2015 | 357 | 0.110 |
Why?
|
| Blotting, Southern | 3 | 2004 | 780 | 0.110 |
Why?
|
| Interleukin-6 | 2 | 2020 | 3201 | 0.110 |
Why?
|
| Iron Overload | 1 | 2015 | 240 | 0.100 |
Why?
|
| Blood Proteins | 2 | 1992 | 1160 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1992 | 685 | 0.100 |
Why?
|
| Transplantation, Homologous | 3 | 2023 | 4668 | 0.100 |
Why?
|
| Precipitin Tests | 2 | 2003 | 815 | 0.100 |
Why?
|
| T-Lymphocytes | 6 | 2023 | 10069 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 2 | 2013 | 1780 | 0.100 |
Why?
|
| Young Adult | 11 | 2024 | 58477 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 58864 | 0.100 |
Why?
|
| Leukopoiesis | 2 | 2002 | 55 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 2925 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2014 | 358 | 0.100 |
Why?
|
| Gene Expression Profiling | 6 | 2019 | 9372 | 0.100 |
Why?
|
| Inpatients | 1 | 2023 | 2580 | 0.100 |
Why?
|
| Binding Sites | 4 | 2006 | 6054 | 0.100 |
Why?
|
| Protein Isoforms | 2 | 2015 | 1695 | 0.100 |
Why?
|
| Receptors, CCR5 | 1 | 2013 | 486 | 0.090 |
Why?
|
| Ribosomes | 1 | 2014 | 497 | 0.090 |
Why?
|
| Community Networks | 1 | 2013 | 201 | 0.090 |
Why?
|
| Blood Platelets | 2 | 2019 | 2522 | 0.090 |
Why?
|
| Microbial Collagenase | 1 | 1991 | 113 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 8050 | 0.090 |
Why?
|
| Zebrafish Proteins | 2 | 2014 | 1008 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1992 | 410 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2448 | 0.090 |
Why?
|
| Adolescent | 12 | 2024 | 87551 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 2 | 2006 | 872 | 0.090 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 339 | 0.090 |
Why?
|
| International Cooperation | 1 | 2017 | 1435 | 0.090 |
Why?
|
| Stilbenes | 1 | 2011 | 155 | 0.090 |
Why?
|
| Leukocyte Count | 4 | 2020 | 1599 | 0.090 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 3018 | 0.090 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2010 | 58 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2023 | 3598 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2015 | 1091 | 0.090 |
Why?
|
| Antigens, CD | 5 | 2003 | 3916 | 0.090 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 1990 | 23 | 0.090 |
Why?
|
| Luciferases | 2 | 2003 | 717 | 0.090 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1998 | 819 | 0.090 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 1375 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 2866 | 0.090 |
Why?
|
| Hospitals | 1 | 2023 | 3929 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2014 | 1588 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 2352 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 508 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 2897 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 4356 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 355 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2016 | 1064 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 3 | 1991 | 1304 | 0.080 |
Why?
|
| Cloning, Molecular | 5 | 1993 | 4170 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2009 | 3729 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2020 | 10181 | 0.080 |
Why?
|
| Hemostasis | 1 | 2012 | 468 | 0.080 |
Why?
|
| Gene Frequency | 1 | 1996 | 3603 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 813 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 1986 | 2524 | 0.080 |
Why?
|
| Cell Nucleus Shape | 1 | 2008 | 16 | 0.080 |
Why?
|
| Transcriptional Activation | 2 | 2007 | 1756 | 0.080 |
Why?
|
| Transduction, Genetic | 2 | 2009 | 897 | 0.080 |
Why?
|
| Curriculum | 1 | 2022 | 3710 | 0.080 |
Why?
|
| Naphthalimides | 1 | 2008 | 22 | 0.080 |
Why?
|
| Autoimmune Diseases | 2 | 2015 | 2236 | 0.080 |
Why?
|
| Disease-Free Survival | 5 | 2020 | 6814 | 0.080 |
Why?
|
| Child | 10 | 2023 | 79604 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 1996 | 1343 | 0.080 |
Why?
|
| Fever | 1 | 2016 | 1619 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 5637 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2014 | 5628 | 0.080 |
Why?
|
| Introns | 2 | 2006 | 976 | 0.080 |
Why?
|
| Opportunistic Infections | 1 | 2011 | 377 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2801 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2003 | 8489 | 0.070 |
Why?
|
| Molecular Biology | 2 | 2023 | 581 | 0.070 |
Why?
|
| Rheumatic Diseases | 1 | 2015 | 640 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2020 | 4492 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2018 | 2161 | 0.070 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2007 | 57 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2011 | 682 | 0.070 |
Why?
|
| Secretory Vesicles | 1 | 2008 | 128 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2012 | 713 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2023 | 80125 | 0.070 |
Why?
|
| Thrombopoiesis | 1 | 2009 | 164 | 0.070 |
Why?
|
| Benzylamines | 1 | 2008 | 232 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2014 | 1265 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1758 | 0.070 |
Why?
|
| Anaplasmosis | 1 | 2007 | 37 | 0.070 |
Why?
|
| Drug Costs | 1 | 2015 | 1183 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 6538 | 0.070 |
Why?
|
| Amino Acid Sequence | 6 | 1998 | 13439 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2017 | 1915 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2014 | 385 | 0.070 |
Why?
|
| Genes, Reporter | 2 | 2003 | 1532 | 0.070 |
Why?
|
| Restriction Mapping | 3 | 1992 | 852 | 0.070 |
Why?
|
| Peroxidase | 3 | 1995 | 603 | 0.070 |
Why?
|
| Receptors, Chemokine | 1 | 2009 | 651 | 0.070 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 2901 | 0.070 |
Why?
|
| Protein Methyltransferases | 1 | 2006 | 54 | 0.070 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1995 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 16878 | 0.070 |
Why?
|
| Mice, Knockout | 4 | 2009 | 14333 | 0.070 |
Why?
|
| tRNA Methyltransferases | 1 | 2006 | 52 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4299 | 0.070 |
Why?
|
| Patient Participation | 1 | 2015 | 1437 | 0.070 |
Why?
|
| COS Cells | 1 | 2008 | 1130 | 0.070 |
Why?
|
| Platelet Count | 2 | 2019 | 776 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3812 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3793 | 0.070 |
Why?
|
| Prothrombin | 1 | 2006 | 191 | 0.070 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1986 | 82 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 943 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2015 | 17748 | 0.060 |
Why?
|
| DNA Restriction Enzymes | 1 | 1985 | 553 | 0.060 |
Why?
|
| Gene Library | 2 | 2002 | 1060 | 0.060 |
Why?
|
| Anthracyclines | 2 | 2020 | 283 | 0.060 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1986 | 169 | 0.060 |
Why?
|
| STAT5 Transcription Factor | 1 | 2006 | 265 | 0.060 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2009 | 176 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 2804 | 0.060 |
Why?
|
| DNA Repair | 1 | 2014 | 2039 | 0.060 |
Why?
|
| Idarubicin | 2 | 2015 | 59 | 0.060 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1986 | 278 | 0.060 |
Why?
|
| Thrombosis | 1 | 2019 | 3042 | 0.060 |
Why?
|
| Daunorubicin | 2 | 2015 | 155 | 0.060 |
Why?
|
| Rhinophyma | 1 | 1984 | 7 | 0.060 |
Why?
|
| Leukemia, Myeloid | 2 | 2006 | 696 | 0.060 |
Why?
|
| Oligodendroglioma | 1 | 2006 | 279 | 0.060 |
Why?
|
| Latin America | 2 | 2017 | 404 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2006 | 673 | 0.060 |
Why?
|
| Developing Countries | 2 | 2017 | 2862 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2010 | 1522 | 0.060 |
Why?
|
| Remission Induction | 1 | 2010 | 2388 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2016 | 3606 | 0.060 |
Why?
|
| Cytogenetics | 1 | 2004 | 198 | 0.060 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2004 | 27 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2017 | 2799 | 0.060 |
Why?
|
| Pregnancy | 3 | 2020 | 29650 | 0.060 |
Why?
|
| Biopsy | 1 | 2016 | 6770 | 0.060 |
Why?
|
| Art | 1 | 1984 | 64 | 0.060 |
Why?
|
| Rosacea | 1 | 1984 | 59 | 0.060 |
Why?
|
| Chromosome Deletion | 3 | 2014 | 1387 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2010 | 1574 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2019 | 41266 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2003 | 38 | 0.050 |
Why?
|
| Immunoglobulins | 2 | 1986 | 863 | 0.050 |
Why?
|
| Dacarbazine | 1 | 2006 | 560 | 0.050 |
Why?
|
| Macrophages | 2 | 2014 | 5723 | 0.050 |
Why?
|
| Leukocyte Elastase | 1 | 2004 | 114 | 0.050 |
Why?
|
| Famous Persons | 1 | 1984 | 109 | 0.050 |
Why?
|
| Cell Survival | 3 | 2020 | 5793 | 0.050 |
Why?
|
| Retroviridae | 2 | 2003 | 850 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2012 | 4263 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 2689 | 0.050 |
Why?
|
| Prevalence | 4 | 2011 | 15639 | 0.050 |
Why?
|
| Paintings | 1 | 1984 | 103 | 0.050 |
Why?
|
| Cell Division | 2 | 2003 | 4445 | 0.050 |
Why?
|
| Survival Rate | 3 | 2024 | 12793 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2011 | 2486 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 1996 | 777 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 6490 | 0.050 |
Why?
|
| Response Elements | 1 | 2003 | 308 | 0.050 |
Why?
|
| Cell Nucleus | 3 | 2000 | 2912 | 0.050 |
Why?
|
| Genomics | 3 | 2022 | 5778 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2007 | 1004 | 0.050 |
Why?
|
| Antigen-Antibody Complex | 1 | 2004 | 513 | 0.050 |
Why?
|
| Phenotype | 4 | 2015 | 16524 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2008 | 1432 | 0.050 |
Why?
|
| Autoantibodies | 2 | 2016 | 2114 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2011 | 1583 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2005 | 3091 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 15750 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2282 | 0.050 |
Why?
|
| Receptors, Erythropoietin | 1 | 2001 | 144 | 0.050 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 1379 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 1986 | 1527 | 0.050 |
Why?
|
| Matched-Pair Analysis | 2 | 2015 | 284 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 15726 | 0.050 |
Why?
|
| Species Specificity | 1 | 2005 | 2408 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2008 | 2666 | 0.040 |
Why?
|
| Cyclins | 1 | 2003 | 594 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2014 | 3730 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2016 | 1674 | 0.040 |
Why?
|
| Proteomics | 2 | 2004 | 3803 | 0.040 |
Why?
|
| Heterozygote | 1 | 2007 | 2796 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2022 | 736 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2003 | 504 | 0.040 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 1999 | 28 | 0.040 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 1999 | 33 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 1054 | 0.040 |
Why?
|
| Retinol-Binding Proteins | 1 | 1999 | 68 | 0.040 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2020 | 234 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2002 | 3600 | 0.040 |
Why?
|
| Membrane Microdomains | 1 | 2020 | 206 | 0.040 |
Why?
|
| Models, Biological | 1 | 2015 | 9460 | 0.040 |
Why?
|
| Transplantation Conditioning | 2 | 2023 | 1592 | 0.040 |
Why?
|
| Liver | 1 | 2015 | 7514 | 0.040 |
Why?
|
| Receptors, Interleukin-8A | 1 | 1998 | 46 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 1998 | 150 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2020 | 10427 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2004 | 1867 | 0.040 |
Why?
|
| Transcription, Genetic | 5 | 2005 | 7593 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 39213 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 162 | 0.040 |
Why?
|
| Age Factors | 1 | 2015 | 18391 | 0.040 |
Why?
|
| Plasmids | 1 | 2003 | 2277 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 342 | 0.040 |
Why?
|
| Risk Factors | 4 | 2021 | 74167 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2008 | 1972 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 1059 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2010 | 2522 | 0.040 |
Why?
|
| RNA | 2 | 2017 | 2719 | 0.040 |
Why?
|
| Lactation Disorders | 1 | 2017 | 14 | 0.040 |
Why?
|
| Vitamin B 12 | 1 | 1981 | 522 | 0.040 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2010 | 131 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 3207 | 0.040 |
Why?
|
| Dimerization | 1 | 1999 | 890 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2013 | 9245 | 0.040 |
Why?
|
| Veterans | 1 | 2011 | 2628 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2013 | 3835 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2022 | 849 | 0.040 |
Why?
|
| Receptors, Interleukin | 1 | 1998 | 243 | 0.040 |
Why?
|
| RNA, Small Interfering | 3 | 2012 | 3443 | 0.040 |
Why?
|
| Receptors, Laminin | 1 | 1996 | 26 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 1293 | 0.030 |
Why?
|
| Integrin alpha6 | 1 | 1996 | 30 | 0.030 |
Why?
|
| Ionomycin | 1 | 1996 | 109 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 1744 | 0.030 |
Why?
|
| Ionophores | 1 | 1996 | 107 | 0.030 |
Why?
|
| United States | 5 | 2023 | 72238 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2016 | 34 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2017 | 574 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2011 | 6531 | 0.030 |
Why?
|
| Immunoglobulin Constant Regions | 2 | 1986 | 58 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2003 | 5039 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 21019 | 0.030 |
Why?
|
| Germ Cells | 1 | 2020 | 635 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2005 | 8312 | 0.030 |
Why?
|
| Antidotes | 1 | 2016 | 139 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2008 | 3045 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2005 | 2441 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 1986 | 4283 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2020 | 12383 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2003 | 1612 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 2016 | 206 | 0.030 |
Why?
|
| Protein Binding | 2 | 2010 | 9334 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 1618 | 0.030 |
Why?
|
| Fetal Death | 1 | 2017 | 430 | 0.030 |
Why?
|
| Connecticut | 1 | 1996 | 364 | 0.030 |
Why?
|
| Placebos | 1 | 2020 | 1672 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1986 | 5423 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1996 | 320 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2011 | 4626 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2000 | 1074 | 0.030 |
Why?
|
| Biological Transport | 1 | 1999 | 2086 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 2192 | 0.030 |
Why?
|
| Clone Cells | 2 | 1990 | 1657 | 0.030 |
Why?
|
| Protein Biosynthesis | 2 | 1992 | 2118 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 611 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1999 | 1833 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 2016 | 366 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1999 | 3087 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 161 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 2756 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1998 | 2176 | 0.030 |
Why?
|
| Age of Onset | 1 | 2020 | 3301 | 0.030 |
Why?
|
| Antithrombins | 1 | 2016 | 313 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 9501 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2020 | 54190 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 21892 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 1995 | 626 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 1439 | 0.030 |
Why?
|
| Uruguay | 1 | 2013 | 104 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1997 | 1494 | 0.030 |
Why?
|
| Defensins | 1 | 1992 | 34 | 0.030 |
Why?
|
| Sulfuric Acid Esters | 1 | 1992 | 31 | 0.030 |
Why?
|
| Leukemia | 2 | 1996 | 1511 | 0.030 |
Why?
|
| Incidence | 2 | 2022 | 21344 | 0.030 |
Why?
|
| Fibronectins | 1 | 1996 | 721 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2000 | 1789 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 20461 | 0.030 |
Why?
|
| Abortion, Spontaneous | 1 | 2017 | 529 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 1999 | 1260 | 0.030 |
Why?
|
| Telomerase | 1 | 2017 | 747 | 0.030 |
Why?
|
| Chile | 1 | 2013 | 251 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 1992 | 261 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1996 | 1752 | 0.030 |
Why?
|
| Antithrombin Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2002 | 283 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3584 | 0.020 |
Why?
|
| Kinetics | 2 | 1995 | 6373 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2007 | 4523 | 0.020 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 1 | 2011 | 195 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1994 | 587 | 0.020 |
Why?
|
| Mucins | 1 | 1995 | 569 | 0.020 |
Why?
|
| Proteome | 1 | 2001 | 1847 | 0.020 |
Why?
|
| Infertility, Female | 1 | 2017 | 762 | 0.020 |
Why?
|
| Toluene | 1 | 2010 | 32 | 0.020 |
Why?
|
| Economics, Pharmaceutical | 1 | 2011 | 87 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 9271 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1991 | 418 | 0.020 |
Why?
|
| Gelatin | 1 | 1992 | 221 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 1992 | 394 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1992 | 4625 | 0.020 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 1990 | 7 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1981 | 4085 | 0.020 |
Why?
|
| Mexico | 1 | 2013 | 755 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 2010 | 156 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1990 | 111 | 0.020 |
Why?
|
| Hemochromatosis | 1 | 2011 | 174 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1996 | 2225 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2022 | 26099 | 0.020 |
Why?
|
| Oncogenes | 1 | 1996 | 1221 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1992 | 460 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2014 | 5841 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2010 | 246 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2016 | 1167 | 0.020 |
Why?
|
| Hematinics | 1 | 2012 | 281 | 0.020 |
Why?
|
| Hematopoietic System | 1 | 1989 | 108 | 0.020 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1990 | 164 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 1996 | 1787 | 0.020 |
Why?
|
| Serum Response Factor | 1 | 2009 | 78 | 0.020 |
Why?
|
| Embryo, Nonmammalian | 1 | 2012 | 900 | 0.020 |
Why?
|
| Brazil | 1 | 2013 | 1211 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1994 | 996 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 1996 | 1665 | 0.020 |
Why?
|
| Ploidies | 1 | 2009 | 275 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2014 | 21992 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 369 | 0.020 |
Why?
|
| Cell Separation | 1 | 2014 | 1720 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3822 | 0.020 |
Why?
|
| Time Factors | 2 | 2003 | 40083 | 0.020 |
Why?
|
| Immunoassay | 1 | 2011 | 748 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2009 | 398 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 1002 | 0.020 |
Why?
|
| Collagen | 1 | 1996 | 2635 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 891 | 0.020 |
Why?
|
| MAP Kinase Kinase 3 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Kidney Transplantation | 2 | 2000 | 4163 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2012 | 1551 | 0.020 |
Why?
|
| Internationality | 1 | 2013 | 1003 | 0.020 |
Why?
|
| Thrombopoietin | 1 | 2009 | 226 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 1999 | 2438 | 0.020 |
Why?
|
| Estradiol | 1 | 2014 | 1931 | 0.020 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1989 | 477 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1999 | 4259 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 1343 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2010 | 9712 | 0.020 |
Why?
|
| Exons | 1 | 1992 | 2389 | 0.020 |
Why?
|
| Genes | 1 | 1989 | 1845 | 0.020 |
Why?
|
| Guanine | 1 | 2006 | 278 | 0.020 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2005 | 68 | 0.020 |
Why?
|
| Milk, Human | 1 | 1989 | 484 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1989 | 1085 | 0.020 |
Why?
|
| Mass Spectrometry | 2 | 2002 | 2190 | 0.020 |
Why?
|
| History, 15th Century | 1 | 1984 | 29 | 0.020 |
Why?
|
| Ataxia Telangiectasia | 1 | 1985 | 107 | 0.010 |
Why?
|
| Calcium | 2 | 1996 | 5718 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1989 | 1690 | 0.010 |
Why?
|
| Antigens, Neoplasm | 2 | 1990 | 2000 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 1985 | 443 | 0.010 |
Why?
|
| Imidazoles | 1 | 2010 | 1175 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1999 | 3417 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 18094 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1990 | 1543 | 0.010 |
Why?
|
| Risk | 1 | 1996 | 9622 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6530 | 0.010 |
Why?
|
| Logistic Models | 2 | 2010 | 13309 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2005 | 333 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 2011 | 1722 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 3091 | 0.010 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2007 | 581 | 0.010 |
Why?
|
| Comorbidity | 1 | 2017 | 10550 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2010 | 2936 | 0.010 |
Why?
|
| Italy | 1 | 1984 | 840 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2002 | 250 | 0.010 |
Why?
|
| Pneumonia | 1 | 1993 | 2139 | 0.010 |
Why?
|
| History, 19th Century | 1 | 1984 | 720 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 6143 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3518 | 0.010 |
Why?
|
| Potassium Cyanide | 1 | 1981 | 17 | 0.010 |
Why?
|
| Ethylmaleimide | 1 | 1981 | 70 | 0.010 |
Why?
|
| HLA-B8 Antigen | 1 | 2000 | 18 | 0.010 |
Why?
|
| Registries | 1 | 2017 | 8435 | 0.010 |
Why?
|
| HLA-B7 Antigen | 1 | 2000 | 50 | 0.010 |
Why?
|
| Spleen | 1 | 2007 | 2274 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2013 | 3062 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12526 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1981 | 343 | 0.010 |
Why?
|
| Zebrafish | 1 | 2012 | 2996 | 0.010 |
Why?
|
| Infant | 1 | 2022 | 35940 | 0.010 |
Why?
|
| Adenine | 1 | 2006 | 976 | 0.010 |
Why?
|
| Hodgkin Disease | 2 | 1986 | 1381 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2000 | 212 | 0.010 |
Why?
|
| RNA Interference | 1 | 2009 | 2848 | 0.010 |
Why?
|
| Piperazines | 1 | 2010 | 2516 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2022 | 41932 | 0.010 |
Why?
|
| Biopolymers | 1 | 2000 | 185 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2000 | 323 | 0.010 |
Why?
|
| Apoptosis | 2 | 2005 | 9470 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 510 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 10825 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2000 | 706 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 11891 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 5499 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2000 | 1432 | 0.010 |
Why?
|
| Pedigree | 1 | 1985 | 4572 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 5197 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 25853 | 0.010 |
Why?
|
| Lymphoma | 1 | 1986 | 1898 | 0.010 |
Why?
|
| Proteins | 2 | 2002 | 6024 | 0.010 |
Why?
|
| Vitamin D | 1 | 2011 | 3291 | 0.010 |
Why?
|
| Iron | 1 | 2005 | 1785 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 12152 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2005 | 1882 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2000 | 980 | 0.010 |
Why?
|
| Rats | 2 | 1989 | 23577 | 0.010 |
Why?
|
| History, 20th Century | 1 | 1984 | 2775 | 0.010 |
Why?
|
| HIV-1 | 1 | 2013 | 6848 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2000 | 1247 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1996 | 1085 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2000 | 607 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1996 | 568 | 0.010 |
Why?
|
| Smoking | 1 | 2010 | 9066 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1985 | 4721 | 0.010 |
Why?
|
| Viral Load | 1 | 2000 | 3317 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2000 | 2282 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1996 | 1122 | 0.010 |
Why?
|
| Graft Survival | 1 | 2000 | 3687 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 15262 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2000 | 5192 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 13285 | 0.010 |
Why?
|
| DNA Probes | 1 | 1989 | 551 | 0.000 |
Why?
|
| Rosette Formation | 1 | 1986 | 152 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1986 | 693 | 0.000 |
Why?
|
| Phytohemagglutinins | 1 | 1985 | 167 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2006 | 24049 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 20027 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1986 | 1607 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1986 | 3482 | 0.000 |
Why?
|
| Skin | 1 | 1986 | 4466 | 0.000 |
Why?
|